210 related articles for article (PubMed ID: 15839953)
1. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic.
Bookman MA
Int J Gynecol Cancer; 2005; 15 Suppl 1():12-7. PubMed ID: 15839953
[TBL] [Abstract][Full Text] [Related]
2. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
[TBL] [Abstract][Full Text] [Related]
3. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
[TBL] [Abstract][Full Text] [Related]
4. [Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
Tsukagoshi S
Gan To Kagaku Ryoho; 1999 Feb; 26(3):393-400. PubMed ID: 10065109
[TBL] [Abstract][Full Text] [Related]
5. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
6. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle effects of gemcitabine.
Cappella P; Tomasoni D; Faretta M; Lupi M; Montalenti F; Viale F; Banzato F; D'Incalci M; Ubezio P
Int J Cancer; 2001 Aug; 93(3):401-8. PubMed ID: 11433406
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Egawa S; Unno M; Terasaki T
Pharm Res; 2012 Jul; 29(7):2006-16. PubMed ID: 22419259
[TBL] [Abstract][Full Text] [Related]
9. Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
Bergman AM; Giaccone G; van Moorsel CJ; Mauritz R; Noordhuis P; Pinedo HM; Peters GJ
Eur J Cancer; 2000 Oct; 36(15):1974-83. PubMed ID: 11000580
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
[TBL] [Abstract][Full Text] [Related]
11. Interaction between cisplatin and gemcitabine in vitro and in vivo.
Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
[TBL] [Abstract][Full Text] [Related]
12. Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells.
Ross DD; Cuddy DP
Biochem Pharmacol; 1994 Oct; 48(8):1619-30. PubMed ID: 7980627
[TBL] [Abstract][Full Text] [Related]
13. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Ruiz van Haperen VW; Veerman G; Boven E; Noordhuis P; Vermorken JB; Peters GJ
Biochem Pharmacol; 1994 Oct; 48(7):1327-39. PubMed ID: 7945430
[TBL] [Abstract][Full Text] [Related]
14. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
Al-Madhoun AS; van der Wilt CL; Loves WJ; Padron JM; Eriksson S; Talianidis I; Peters GJ
Biochem Pharmacol; 2004 Aug; 68(4):601-9. PubMed ID: 15276067
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
van Moorsel CJ; Bergman AM; Veerman G; Voorn DA; Ruiz van Haperen VW; Kroep JR; Pinedo HM; Peters GJ
Biochim Biophys Acta; 2000 Mar; 1474(1):5-12. PubMed ID: 10699484
[TBL] [Abstract][Full Text] [Related]
16. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
Hodge LS; Taub ME; Tracy TS
Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders.
Santini V; Bernabei A; Gozzini A; Scappini B; Zoccolante A; D'Ippolito G; Figuccia M; Ferrini PR
Haematologica; 1997; 82(1):11-5. PubMed ID: 9172997
[TBL] [Abstract][Full Text] [Related]
18. Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells.
Bhalla K; Holladay C; Lutzky J; Ibrado AM; Bullock G; Jasiok M; Singh S
Gynecol Oncol; 1992 Apr; 45(1):32-9. PubMed ID: 1601333
[TBL] [Abstract][Full Text] [Related]
19. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
Abbruzzese JL; Grunewald R; Weeks EA; Gravel D; Adams T; Nowak B; Mineishi S; Tarassoff P; Satterlee W; Raber MN
J Clin Oncol; 1991 Mar; 9(3):491-8. PubMed ID: 1999720
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.
Grunewald R; Kantarjian H; Du M; Faucher K; Tarassoff P; Plunkett W
J Clin Oncol; 1992 Mar; 10(3):406-13. PubMed ID: 1740680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
